[1. Friedman Set Blumberg S. Chapter 295 Inflammatory Bowel Disease. In: Harrison’s Principles of Internal Medicine, 18 edition, Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, USA, 2012.]Search in Google Scholar
[2. Ha F et Khalil H. Crohn’s disease: a clinical update. Ther Adv Gastroenterol, 2015, 8(6), 352-359.10.1177/1756283X15592585]Search in Google Scholar
[3. Levine JS et Burakoff B. Extraintestinal Manifestations of Inflammatory Bowel Disease. Gastroenterology & Hepatology, 2011, 7(4), 235-241.]Search in Google Scholar
[4. Bernstein CN, Fried M, Krabshuis JH et al. World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010. Inflammatory Bowel Diseases, 2010, 16(1), 112-114.10.1002/ibd.21048]Open DOISearch in Google Scholar
[5. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol, 2006, 12(30), 4819-31.10.3748/wjg.12.4819]Search in Google Scholar
[6. Vavricka SR, Schoepfer A, Scharl M et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis, 2015, 21, 1982-1992.10.1097/MIB.0000000000000392]Search in Google Scholar
[7. Spekhorst LM, Imhann F, Festen EA on behalf of the Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC), et al. Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. BMJ Open, 2017, 7, e016695.10.1136/bmjopen-2017-016695]Search in Google Scholar
[8. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 55, 749-753.10.1136/gut.2005.082909]Search in Google Scholar
[9. Freeman HJ. Natural history and long-term clinical course of Crohn’s disease. World J Gastroenterol, 2014, 20(1), 31-36.10.3748/wjg.v20.i1.31]Open DOISearch in Google Scholar
[10. Hellers G. Crohn’s disease in Stockholm county 1955-1974. A study of epidemiology, results of surgical treatment and longterm prognosis. Acta Chir Scand Suppl, 1979, 490, 1-84.]Search in Google Scholar
[11. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis, 2002, 8(4), 244-50.10.1097/00054725-200207000-00002]Open DOISearch in Google Scholar
[12. Fedorak RN. Is it time to re-classify Crohn’s disease? Best Pract Res Clin Gastroenterol, 2004, 18 Suppl, 99-106.10.1016/j.bpg.2004.06.018]Open DOISearch in Google Scholar
[13. Herfarth HH, Long MD, Kappelman MD. Immunosuppression for management of Crohn’s disease. The Lancet, 2016, 387(10020), 747-748.10.1016/S0140-6736(16)00327-5]Search in Google Scholar
[14. Khanna, R, Bressler, B, Levesque, BG et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet, 2015, 386, 1825-1834.10.1016/S0140-6736(15)00068-9]Search in Google Scholar
[15. D’Haens, G, Baert, F, van Assche, G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet, 2008, 371, 660-667.10.1016/S0140-6736(08)60304-9]Search in Google Scholar
[16. Colombel, JF, Sandborn, WJ, Reinisch, W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med, 2010, 362, 1383-1395.10.1056/NEJMoa090449220393175]Search in Google Scholar
[17. Lakatos PL, Lakatos L, Kiss LS et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion, 2012, 86 (Suppl 1), 28-35.10.1159/00034195023051724]Search in Google Scholar
[18. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res, 2012, 159(4), 313-25.10.1016/j.trsl.2012.01.001330811622424434]Search in Google Scholar
[19. Benor S, Russell GH, Silver M et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics, 2010, 125(6), 1230-6.10.1542/peds.2009-193620439597]Search in Google Scholar
[20. Velikova TV. Investigations of immunological parameters for intestinal inflammation in order to establish new markers for diagnosis and follow-up of inflammatory bowel disease. Dissertation 2014. Medical university of Sofia.]Search in Google Scholar
[21. Lewis JD. The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology, 2011, 140(6), 1817-1826.10.1053/j.gastro.2010.11.058374929821530748]Search in Google Scholar